Candesartan cilexetil in heart failure assessment of reduction in mortality and morbidity (CHARM Preserved)

Study identifier:SH-AHS-0007

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Candesartan cilexetil in heart failure assessment of reduction in mortality and morbidity. Clinical Study of Candesartan in Patients with heart failure and preserved left ventricular systolic function

Medical condition

Congestive Heart Failure

Phase

Phase 3

Healthy volunteers

No

Study drug

Candesartan, Placebo

Sex

All

Actual Enrollment

734

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jun 1999
Primary Completion Date: 01 May 2003
Study Completion Date: 01 May 2003

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria